13F Holdings
中文EN

CTTH CTT PHARMACEUTICAL HOLDINGS, INC.

Pharmaceutical Preparations · OTC · SEC CIK 1035422 · Fiscal year ends 12/31

Financial factors as of 2015-09-30 (2015Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-1,345.6%
TTM EPS YoY-500.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-207.0%
ROA-146.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets20.0%
Debt / equity0.00x
Current ratio—
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.17x
Accruals ratio-121.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2015Q32015-09-302015Q22015-06-302015Q12015-03-312014Q4*2014-12-312014Q32014-09-302014Q22014-06-302014Q12014-03-312013Q4*2013-12-31
Income statement
Revenue————————
SG&A expense$14,934$4,466$34,882$4,573$12,946$916$907$884
Operating income——-$337,052——-$22,322-$1,673$240,793
Net income-$341,930-$362,657-$337,052$271,481-$43,196-$920-$1,673-$7,487
EPS (basic)-0.030.00-0.02—-0.010.00-0.01—
EPS (diluted)-0.030.00-0.02—-0.010.00-0.01—
Weighted avg. shares (diluted)21.32M21.32M19.51M—15.77M14.92M14.92M—
Balance sheet
Cash & equivalents$32,121$46,073$73,447$81,179$125,318$3,669$4,545$0
Short-term investments———————$0
Receivables$5,430$5,430$5,430$5,430$5,430$5,429$5,429$0
Current assets$922,038$958,688$1.04M$1.05M———$6,252
Total assets$922,038$1.18M$1.42M$1.66M$130,748$227,543$17,219$0
Current liabilities———————$249,378
Total liabilities$183,960$156,373$211,696$169,490$124,600$141,987$279,868$29,322
Shareholders' equity$738,078$1.03M$1.21M$1.49M$6,148$85,556-$262,649-$29,322
Shares outstanding21.32M21.32M19.51M19.51M184.37M35.18M9.41M14.92M
Cash flow statement
Operating cash flow-$15,527-$29,158-$39,652-$46,837$20,869-$28,737-$330-$209
Investing cash flow———-$1$271,069-$147,689$28,512$3,703
Financing cash flow-$959$2,787$28,550—-$386,750$386,750$4,875$0
Stock-based compensation$46,408$49,166$43,650————$0

Free plan shows the latest 8 periods; Pro shows all 22 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.